Page 1094 - Hematology_ Basic Principles and Practice ( PDFDrive )

969.e8 Part VII Hematologic Malignancies

325. Wimazal F, Sperr WR, Kundi M, et al: Prognostic value of lactate 345. Kulasekararaj AG, Jiang J, Smith AE, et al: Somatic mutations identify
dehydrogenase activity in myelodysplastic syndromes. Leuk Res 25(4): a subgroup of aplastic anemia patients who progress to myelodysplastic
287–294, 2001. syndrome. Blood 124(17):2698–2704, 2014.
326. Economopoulos T, Economidou J, Giannopoulos G, et al: Immune 346. Iwanaga M, Furukawa K, Amenomori T, et al: Paroxysmal nocturnal
abnormalities in myelodysplastic syndromes. J Clin Pathol 38(8):908– haemoglobinuria clones in patients with myelodysplastic syndromes. Br
911, 1985. J Haematol 102(2):465–474, 1998.
327. Mufti GJ, Figes A, Hamblin TJ, et al: Immunological abnormalities in 347. Sokol L, Loughran TP: Large granular lymphocyte leukemia. Oncologist
myelodysplastic syndromes. I. Serum immunoglobulins and autoanti- 11(3):263–273, 2006.
bodies. Br J Haematol 63(1):143–147, 1986. 348. Lane AA, Odejide O, Kopp N, et al: Low frequency clonal muta-
328. Senent L, Arenillas L, Luño E, et al: Reproducibility of the World tions recoverable by deep sequencing in patients with aplastic anemia.
Health Organization 2008 criteria for myelodysplastic syndromes. Leukemia 27(4):968–971, 2013.
Haematologica 98(4):568–575, 2013. 349. Yoshizato T, Dumitriu B, Hosokawa K, et al: Somatic mutations and
329. Font P, Loscertales J, Benavente C, et al: Inter-observer variance with clonal hematopoiesis in aplastic anemia. N Engl J Med 373(1):35–47,
the diagnosis of myelodysplastic syndromes (MDS) following the 2008 2015.
WHO classification. Ann Hematol 92(1):19–24, 2013. 350. Koskela HLM, Eldfors S, Ellonen P, et al: Somatic STAT3 mutations in
330. Greenberg P, Cox C, LeBeau MM, et al: International scoring large granular lymphocytic leukemia. N Engl J Med 366(20):1905–1913,
system for evaluating prognosis in myelodysplastic syndromes. Blood 2012.
89(6):2079–2088, 1997. 351. Ohyashiki K, Sasao I, Ohyashiki JH, et al: Clinical and cytogenetic
331. Greenberg PL, Tuechler H, Schanz J, et al: Revised international characteristics of myelodysplastic syndromes developing myelofibrosis.
prognostic scoring system for myelodysplastic syndromes. Blood Cancer 68(1):178–183, 1991.
120(12):2454–2465, 2012. 352. Rumi E, Pietra D, Pascutto C, et al: Clinical effect of driver muta-
332. Kantarjian H, O’Brien S, Ravandi F, et al: Proposal for a new risk tions of JAK2, CALR, or MPL in primary myelofibrosis. Blood
model in myelodysplastic syndrome that accounts for events not con- 124(7):1062–1069, 2014.
sidered in the original International Prognostic Scoring System. Cancer 353. Zhang S-J, Rampal R, Manshouri T, et al: Genetic analysis of patients
113(6):1351–1361, 2008. with leukemic transformation of myeloproliferative neoplasms shows
333. Garcia-Manero G, Shan J, Faderl S, et al: A prognostic score for patients recurrent SRSF2 mutations that are associated with adverse outcome.
with lower risk myelodysplastic syndrome. Leukemia 22(3):538–543, Blood 119(19):4480–4485, 2012.
2008. 354. Kantarjian HM, Keating MJ, Walters RS, et al: Therapy-related
334. Malcovati L, Della Porta MG, Strupp C, et al: Impact of the degree of leukemia and myelodysplastic syndrome: clinical, cytogenetic, and
anemia on the outcome of patients with myelodysplastic syndrome and prognostic features. J Clin Oncol 4(12):1748–1757, 1986.
its integration into the WHO classification-based Prognostic Scoring 355. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adju-
System (WPSS). Haematologica 96(10):1433–1440, 2011. vant chemotherapy for early-stage breast cancer: the Eastern Cooperative
335. Voso MT, Fenu S, Latagliata R, et al: Revised International Prognostic Oncology Group experience. J Clin Oncol 13(7):1557–1563, 1995.
Scoring System (IPSS) predicts survival and leukemic evolution of 356. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and
myelodysplastic syndromes significantly better than IPSS and WHO myelodysplastic syndrome after doxorubicin-cyclophosphamide adju-
Prognostic Scoring System: validation by the Gruppo Romano Mielo- vant therapy for operable breast cancer: the National Surgical Adjuvant
displasie Italian Regional Database. J Clin Oncol 31(21):2671–2677, Breast and Bowel Project Experience. J Clin Oncol 21(7):1195–1204,
2013. 2003.
336. Neukirchen J, Lauseker M, Blum S, et al: Validation of the revised 357. Darrington DL, Vose JM, Anderson JR, et al: Incidence and character-
international prognostic scoring system (IPSS-R) in patients with ization of secondary myelodysplastic syndrome and acute myelogenous
myelodysplastic syndrome: a multicenter study. Leuk Res 38(1):57–64, leukemia following high-dose chemoradiotherapy and autologous stem-
2014. cell transplantation for lymphoid malignancies. J Clin Oncol 12(12):
337. Zeidan AM, Lee J-W, Prebet T, et al: Comparison of the prognostic 2527–2534, 1994.
utility of the revised International Prognostic Scoring System and the 358. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with
French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndrome after autologous bone marrow transplanta-
myelodysplastic syndromes. Br J Haematol 166(3):352–359, 2014. tion for non-Hodgkin’s lymphoma. J Clin Oncol 17(10):3128–3135,
338. Della Porta MG, Alessandrino EP, Bacigalupo A, et al: Predictive factors 1999.
for the outcome of allogeneic transplantation in patients with MDS 359. Palumbo A, Bringhen S, Kumar SK, et al: Second primary malignancies
stratified according to the revised IPSS-R. Blood 123(15):2333–2342, with lenalidomide therapy for newly diagnosed myeloma: a meta-
2014. analysis of individual patient data. Lancet Oncol 15(3):333–342, 2014.
339. Komrokji RS, Corrales-Yepez M, Al Ali N, et al: Validation of the MD 360. Andersen MK, Christiansen DH, Pedersen-Bjergaard J: Centromeric
Anderson Prognostic Risk Model for patients with myelodysplastic breakage and highly rearranged chromosome derivatives associated
syndrome. Cancer 118(10):2659–2664, 2012. with mutations of TP53 are common in therapy-related MDS and
340. van Spronsen MF, Ossenkoppele GJ, Holman R, et al: Improved risk AML after therapy with alkylating agents: an M-FISH study. Genes
stratification by the integration of the revised international prognostic Chromosomes Cancer 42(4):358–371, 2005.
scoring system with the myelodysplastic syndromes comorbidity index. 361. Pedersen-Bjergaard J: Radiotherapy- and chemotherapy-induced myelo-
Eur J Cancer 1990 50(18):3198–3205, 2014. dysplasia and acute myeloid leukemia. A review. Leuk Res 16(1):61–65,
341. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prog- 1992.
nostic scoring system for predicting survival and leukemic evolution in 362. Mistry AR, Felix CA, Whitmarsh RJ, et al: DNA topoisomerase II in
myelodysplastic syndromes. J Clin Oncol 25(23):3503–3510, 2007. therapy-related acute promyelocytic leukemia. N Engl J Med 352(15):
342. Della Porta MG, Tuechler H, Malcovati L, et al: Validation of WHO 1529–1538, 2005.
classification-based Prognostic Scoring System (WPSS) for myelodys- 363. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associa-
plastic syndromes and comparison with the revised International Prog- tions in 306 patients with therapy-related myelodysplasia and myeloid
nostic Scoring System (IPSS-R). A study of the International Working leukemia: the University of Chicago series. Blood 102(1):43–52, 2003.
Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 2015. 364. Fukumoto JS, Greenberg PL: Management of patients with higher risk
343. Van den Berghe H, Cassiman JJ, David G, et al: Distinct haematologi- myelodysplastic syndromes. Crit Rev Oncol Hematol 56(2):179–192,
cal disorder with deletion of long arm of no. 5 chromosome. Nature 2005.
251(5474):437–438, 1974. 365. Abruzzese E, Radford JE, Miller JS, et al: Detection of abnormal pre-
344. Sokal G, Michaux JL, Van Den Berghe H, et al: A new hematologic transplant clones in progenitor cells of patients who developed myelo-
syndrome with a distinct karyotype: the 5 q–chromosome. Blood dysplasia after autologous transplantation. Blood 94(5):1814–1819,
46(4):519–533, 1975. 1999.